BACKGROUND: The purpose of this study was to evaluate the use of raster-scanned intensity-controlled @entity505 ion therapy (ICCT) in the treatment of @entity320 of the paranasal sinus. METHODS: @entity1 received combined intensity-modulated radiotherapy (IMRT) plus @entity505 ion (C12). Records of 18 consecutive @entity1 treated between 2009 and 2013 were analyzed retrospectively regarding @entity137 (Common Terminology Criteria for Adverse Events, version 4), treatment response (Response Evaluation Criteria in Solid Tumors [RECIST]), and control/survival rates. RESULTS: Most @entity1 had @entity1442 (T4, 94%; gross @entity66 , 78%). Median dose was 74 GyE (median boost volume   =   157 mL). C12 treatments were planned as ICCT, no concurrent chemotherapy was administered. Grade III or higher late @entity137 was not observed. @entity1349 ( @entity1349 ), progression-free survival (PFS), and locoregional control at 3 years were 16.2%, 0%, and 58.3%, respectively (median follow-up, 18 months). Resection status did not impact locoregional control or survival rates. CONCLUSION: ICCT results in promising locoregional control at mild @entity137 . @entity1349 is poor because of the occurrence of distant metastases; therefore, addition of systemic components to primary treatment should be investigated.    2015 Wiley Periodicals, Head Neck 38: E1445-E1451, 2016.

Raster-scanned intensity-controlled @entity505 ion therapy for XXXX of the paranasal sinus.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity66 :: ('MESH:D004194', 'Disease') :: ['residual disease'] @entity1442 :: ('MESH:D020178', 'Disease') :: ['advanced disease'] @entity505 :: ('MESH:D002244', 'Chemical') :: ['carbon'] @entity320 :: ('MESH:D008545', 'Disease') :: ['mucosal melanoma'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'Overall survival']
@entity320 :: (MESH:D008545,Disease) :: ['mucosal melanoma']
